|On the pathway to beat polycythemia vera/ by Zhen||One of the great mysteries about JAK2 inhibitors is they seem to work whether or not a patient has the mutation. This was one of the findings that led Shauguang Li to zero in on genes downstream of the JAK2 signalling that may be decisive in developing PV. Part of the “Behind the Lab Door,” series.|
|Ask the doctors||In the first joint media interview after Ruxolitinib released its strongly positive results, Drs. Srdan Verstovsek and Ruben Mesa answer the key questions and present their posters.|
|Ruxolitinib on Trial/ by Zhen||“For the first time we have a treatment (for MF),” said trial investigator Dr. Claire Harrison of Guy’s and St. Thomas, London “that meaningfully reduces spleen size and addresses the burden of disabling symptoms.”This is the extensive coverage of ruxolitinib from before its dramatic successes were reported at the ASCO meeting in Chicago through its presentation by Drs. Verstovsek and Mesa.|
|Tefferi Drops the Other Shoe/ by Zhen||Amid the euphoria over Jakafi’s approval y the FDA, Dr.Ayalew Tefferi launched a blistering counter-attack, first in the NEJM (see NYC goes MPD) and now in a YouTube video presenting his study of 1000 Mayo Clinic patients.
Leave a Reply